Estimation of plasma IC50 of donepezil for cerebral acetylcholinesterase inhibition in patients with Alzheimer disease using positron emission tomography

Clinical Neuropharmacology

Volumn 33, Issue 2, 2010, Pages 74-78

  Ota, Tsuneyoshi ^a,b   Shinotoh, Hitoshi ^a,c   Fukushi, Kiyoshi ^a   Kikuchi, Tatsuya ^a   Sato, Koichi ^a,d   Tanaka, Noriko ^a,e   Shimada, Hitoshi ^a,f   Hirano, Shigeki ^a,g   Miyoshi, Michie ^a   Arai, Heii ^b   Suhara, Tetsuya ^a   Irie, Toshiaki ^a  

^a NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

^b JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c Asahi Hospital for Neurological Diseases   (Japan)

^d TEIKYO UNIVERSITY CHIBA MEDICAL CENTER   (Japan)

^e TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^f CHIBA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g JR Tokyo General Hospital   (Japan)

Author keywords

Acetylcholinesterase; Alzheimer disease; Donepezil; In vivo plasma IC50; Positron emission tomography

Indexed keywords

ACETYLCHOLINESTERASE; CARBON 11; DONEPEZIL; N [CARBON 11] METHYLPIPERIDIN 4 YL ACETATE; UNCLASSIFIED DRUG;

ADULT; ALZHEIMER DISEASE; ARTICLE; BRAIN CORTEX; CLINICAL ARTICLE; DRUG DOSE INCREASE; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HUMAN; IC 50; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

ACETYLCHOLINESTERASE; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CEREBRAL CORTEX; CHOLINESTERASE INHIBITORS; FEMALE; HUMANS; INDANS; INHIBITORY CONCENTRATION 50; MALE; MIDDLE AGED; PIPERIDINES; POSITRON-EMISSION TOMOGRAPHY;

EID: 77951026072     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/WNF.0b013e3181c71be9     Document Type: Article

References (40)

1. Rogers SL, Friedhoff LT, the Donepezil Study Group. The efficacy and safety of donepezil in patients with AD: results of a US multicentre, randomized, double-blind, placebo-controlled trial. Dementia 1996;7:293-303.
2. Kimura M, Asasofu S, Ogura H, et al. Protective effect of donepezil against Abeta (1-40) neurotoxicity in rat septal neurons. Brain Res 2005;14:72-84.
3. Ballard CG, Chalmers KA, Todd C, et al. Cholinesterase inhibitors reduce cortical Abeta in dementia with Lewy bodies. Neurology 2007;68:1726-1729.
4. Van Dam D, Coen K, De Deyn PP. Cognitive evaluation of disease-modifying efficacy of donepezil in the APP 23 mouse model for Alzheimer's disease. Psychopharmacology (Berl) 2008;197:37-43.
5. Irie T, Fukushi K, Akimoto Y, et al. Design and evaluation of radioactive acetylcholine analogues for mapping brain acetylcholinesterase (AChE) in vivo. Nucl Med Biol 1994;21:801-808.
6. Kilbourn MR, Snyder SE, Sherman PS, et al. In vivo studies of acetylcholinesterase activity using a labeled substrate, N-[11C]methylpiperidin- 4-yl propionate ([11C]PMP). Synapse 1996;22:123-131.
7. Namba H, Iyo M, Fukushi K, et al. Human cerebral acetylcholinesterase activity measured with positron emission tomography: procedure, normal value and effect of age. Eur J Nucl Med 1999;26:135-143.
8. Koeppe RA, Frey KA, Snyder SE, et al. Kinetic modeling of N-[11C]methylpiperidin-4-yl propionate: alternatives for analysis of an irreversible positron emission tomography tracer for measurement of acetylcholinesterase activity in human brain. J Cereb Blood Flow Metab 1999;19:1150-1163.
9. Iyo M, Namba H, Fukushi K, et al. Measurement of acetylcholinesterase by positron emission tomography in the brains of healthy controls and patients with Alzheimer's disease. Lancet 1997;349:1805-1809.
10. Kuhl DE, Koeppe RA, Minoshima S, et al. In vivo mapping of cerebral acetylcholinesterase activity in aging and Alzheimer's disease. Neurology 1999;52:691-699.
11. Shinotoh H, Namba H, Yamaguchi M, et al. Positron emission tomographic measurement of acetylcholinesterase activity reveals differential loss of ascending cholinergic systems in Parkinson's disease and progressive supranuclear palsy. Ann Neurol 1999;46:62-69.
12. Kuhl DE, Minoshima S, Frey KA, et al. Limited donepezil inhibition of acetylcholinesterase measured with positron emission tomography in living Alzheimer's cerebral cortex. Ann Neurol 2000;48:391-395.
13. Shinotoh H, Aotsuka A, Fukushi K, et al. Effect of donepezil on brain acetylcholinesterase activity in patients with AD measured by PET. Neurology 2001;56:408-410.
14. Kaasinen V, Någren K, Jävenpää T, et al. Regional effects of donepezil and rivastigmine on cortical acetylcholinesterase activity in Alzheimer's disease. J Clin Psychopharmacol 2002;22:615-620.
15. Bohnen NI, Kaufer DI, Hendrickson R, et al. Degree of inhibition of acetylcholinesterase activity and cognitive effects by donepezil treatment in Alzheimer's disease. J Neurol Neurosurg Psychiatry 2005;76:315-319.
16. Tsukada H, Nishiyama S, Fukumoto D, et al. Effects of acute acetylcholinesterase inhibition on the cerebral cholinergic neuronal system and cognitive function: functional imaging of the conscious monkey brain using animal PET in combination with microdialysis. Synapse 2004;52:1-10.
17. Shiraishi T, Kikuchi T, Fukushi K, et al. Estimation of plasma IC50 of donepezil hydrochloride for brain acetylcholinesterase inhibition in monkey using N-[11C]methylpiperidin-4-yl acetate ([11C]MP4A) and PET. Neuropsychopharmacology 2005;30:2154-2161.
18. Kadir A, Darreh-Shori T, Almkvist O, et al. PET imaging of the in vivo brain acetylcholinesterase activity and nicotine binding in galantamine-treated patient with AD. Neurobiol Aging 2008;29: 1204-1217.
19. Kasa P, Papp H, Kasa P Jr, et al. Donepezil dose-dependently inhibits acetylcholinesterase activity in various areas and in the presynaptic cholinergic and the postsynaptic cholinoceptive enzyme-positive structures in human and rat brain. Neuroscience 2000;101:89-100.
20. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDAWork Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984;34:939-944.
21. Namba H, Tanaka N, Matsuura H, et al. Pixel-by-pixel mapping of acetylcholinesterase activity in human brain with [11C]MP4A/PET. In: Senda M, Kimura Y, Herscovitch P, ed. Brain Imaging Using PET. 1st ed. San Diego, CA: Academic Press; 2002:55-61.
22. Mizumura S, Kumita S, Cho K, et al. Development of quantitative analysis method for stereotactic brain image: assessment of reduced accumulation in extent and severity using anatomical segmentation. Ann Nucl Med 2003;17:289-295.
23. Lancaster JL, Woldorff MG, Parsons LM, et al. Automated Talairach Atlas labels for functional brain mapping. Hum Brain Mapp 2000;10:120-131.
24. Lee JW, Rogers SL, Friedhoff LT, et al. Validation and application of an HPLC method for the determination on 1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-yl] methyl piperidine HCl (E2020) in human plasma. Pharm Res 1992;9:S338.
25. Rogers SL, Friedhoff LT. Pharmacokinetic and pharmacodynamic profile of donepezil HCl following single oral doses. Br J Clin Pharmacol 1998a;46(suppl 1):1-6.
26. Carson RE. Parameter estimation in positron emission tomography. In: Phelps M, Mazziotta J, Schelbert H, ed. Positron Emission Tomography and Autoradiography: Principles and Applications for the Brain and Heart. New York: Raven Press; 1986:347-390.
27. Veng PP. Curve fitting and modeling in pharmacokinetics and some practical experiences with NONLIN and a new program FUNFIT. J Pharmacokinet Biopharm 1977;5:513-531.
28. Bonnot-Lours S, Prenant C, Crouzel C. Synthesis of 9-[11C]methylamino-1, 2,3,4-tetrahydroacridine, a potent acetylcholinesterase inhibitor. Appl Radiat Isot 1991;41:690-691.
29. Traykov L, Tavitian B, Jobert A, et al. In vivo PET study of cerebral [11C]methyl-tetrahydroaminoacridine distribution and kinetics in healthy human subjects. Eur J Neurol 1999;6:273-278.
30. Pappata S, Tavitian B, Traykov L, et al. In vivo imaging of human cerebral acetylcholinesterase. J Neurochem 1996;67:876-879.
31. Okamura N, Funaki Y, Tashiro M, et al. In vivo visualization of donepezil binding in the brain of patients with Alzheimer's disease. Br J Clin Pharmacol 2008;65:472-479.
32. Musachio JL, Flesher JE, Scheffel UA, et al. Radiosynthesis and mouse brain distribution studies of [11C]CP-126,998: a PET ligand for in vivo study of acetylcholinesterase. Nucl Med and Biol 2002;29: 547-552.
33. Kikuchi T, Okamura T, Fukushi K, et al. Cerebral acetylcholinesterase imaging: development of the radioprobes. Curr Top Med Chem 2007;18:1790-1799.
34. Kato K, Hayako H, Ishihara Y, et al. TAK-147, an acetylcholinesterase inhibitor, increases choline acetyltransferase activity in cultured rat septal cholinergic neurons. Neurosci Lett 1999;260:5-8.
35. Irie T, Fukushi K, Namba H, et al. Brain acetylcholinesterase activity: validation of a PET tracer in a rat model of Alzheimer's disease. J Nucl Med 1996;37:649-655.
36. Rogers SL, Farlow MR, Doody RS, et al. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology 1998b;50:136-145.
37. Tiseo PJ, Rogers SL, Friedhoff LT. Pharmacokinetic and pharmacodynamic profile of donepezil HCl following evening administration. Br J Clin Pharmacol 1998;46(suppl 1):13-18.
38. Mihara M, Ohnishi A, Tomono Y, et al. Pharmacokinetics of E2020, a new compound for Alzheimer's disease, in healthy male volunteers. Int J Clin Pharmacol Ther Toxicol 1993;31:223-229.
39. Yamanishi Y, Kosasa T, Kuriya Y. Inhibitory effect of donepezil hydrochloride on cholinesterase activities in vitro. Jpn Pharmacol Ther 1998;26(suppl):1277-1282 (in Japanese).
40. Ogura H, Kosasa T, Kuriya Y, et al. Comparison of inhibitory activities of donepezil and other cholinesterase inhibitors on acetylcholinesterase and butyrylcholinesterase in vitro. Methods Find Exp Clin Pharmacol 2000;22:609-613.